MedBalans

Primary pathogens (Polymicrobial perianal flora — Escherichia coli · Bacteroides and anaerobes · Staphylococcus aureus · Streptococcus species · enteric Gram-negative bacilli)
Clinical context (Acute perianal/perirectal abscess (paraproctitis) — predominantly infants <2 years; conservative management with hygiene and sitz baths is widely used; antibiotics not routine (APSA 2025, StatPearls))

First-line therapy

Amoxicillin/clavulanate • p.o. • 22.5–22.5 mg/kg/dose • 2×/day

Dose is calculated using the amoxicillin component.

Max 875 mg/dose (amoxicillin) · Max 1750 mg/day · Duration: 7–10 days · Only when antibiotics clinically indicated — 45 mg/kg/day amoxicillin component divided BID; step-down after IV therapy when stable

• Antibiotics are NOT routinely required for uncomplicated paraproctitis — APSA 2025 systematic review: no superiority of antibiotics alone or routine post-drainage antibiotics in most infants.
• Conservative management first: perianal hygiene, warm sitz baths, analgesia, and observation — complete resolution in ~60% of infants with NOM (APSA OEBPC 2025).

• Oral amoxicillin/clavulanate when indicated: systemic signs (fever, toxicity), significant perianal cellulitis, immunocompromise, failure of conservative care or drainage, or clinician judgment in complicated cases (StatPearls, Johns Hopkins All Children's SSTI pathway).
• Do not treat with antibiotics alone without drainage when fluctuant abscess present — I&D (or spontaneous drainage) is definitive; antibiotics are adjunctive only (StatPearls, IDSA abscess principles).
• Refer deep, horseshoe, or ischiorectal abscess to pediatric surgery — not manageable as simple outpatient paraproctitis (StatPearls, APSA).

Enter weight on Kids to calculate doses

Clindamycin • p.o. • 10–10 mg/kg/dose • 3×/day

Max 600 mg/dose · Max 1800 mg/day · Duration: 7–10 days · Covers anaerobes, streptococci, and most CA-MRSA if susceptible — verify local resistance; does not cover all enteric Gram-negatives

• Clindamycin: non-anaphylactic penicillin allergy when oral anaerobic + Gram-positive coverage needed — alternative to amoxicillin/clavulanate (Johns Hopkins All Children's, SIU pediatric empiric guidelines).
• Metronidazole plus cephalosporin: alternative anaerobic regimen in older children when clindamycin unsuitable — per adult perirectal pathways; specialist-guided in pediatrics (StatPearls perirectal abscess).
• Conservative management without antibiotics: preferred initial approach for well-appearing infant with small early perianal abscess — shared decision-making with caregivers (APSA 2025, Translational Gastroenterology narrative review).
• I&D indications: fluctuant abscess, failure of conservative care, worsening pain/swelling, or parental preference after counseling — incision close to anal verge; pediatric surgery referral if recurrent or fistula suspected (APSA, StatPearls).
• Wound culture when antibiotics prescribed: especially prior antibiotic exposure, treatment failure, or immunocompromise — tailor therapy to susceptibilities (StatPearls, Johns Hopkins All Children's).

Enter weight on Kids to calculate doses

Clinical notes

• Conservative treatment indications: well-appearing infant with small perianal abscess, no systemic toxicity, reliable follow-up — hygiene, sitz baths, analgesia; NOM failure ~37.5% per APSA 2025 (APSA OEBPC systematic review).

• I&D indications: fluctuant collection, persistent or enlarging abscess despite conservative care, significant pain, or caregiver/surgeon preference — primary treatment for drainable abscess; do not rely on antibiotics alone (StatPearls, IDSA).
• Antibiotics after drainage: NOT routine for simple drained perianal abscess in immunocompetent child — consider when systemic infection, surrounding cellulitis, immunocompromise, or clinical failure (StatPearls strong recommendation; APSA 2025 no routine post-drainage benefit demonstrated).
• Wound culture: obtain when starting antibiotics, recurrent paraproctitis, prior antibiotic failure, or at I&D when culture will change management — not routinely needed if not prescribing antibiotics (StatPearls, Johns Hopkins All Children's).
• Recurrence and fistula-in-ano (FIA): recurrence ~21–24% after NOM or I&D; FIA develops in ~20% regardless of initial strategy — pediatric surgery follow-up if persistent perianal drainage, recurrent abscess, or palpable tract (APSA 2025; follow-up 48–72 h, sooner if worsening).

• APSA OEBPC — Management of perianal abscesses in infants (systematic review) (2025)
• StatPearls — Perianal abscess and perirectal abscess (2024)
• AAP Red Book — Skin and soft tissue infections (principles applicable) (2024)

+ 5 more

• IDSA — Skin and soft tissue infection guidelines (abscess principles) (2014)
• ESPID — Skin and soft tissue infection guidance (2024)
• CPS — Community-associated bacterial SSTI in children (principles applicable) (2024)
• Johns Hopkins All Children's — Skin and soft tissue infections pathway (2024)
• Translational Gastroenterology and Hepatology — Conservative vs operative perianal abscess in infants (2023)

Paraproctitis

First-line therapy

Clinical notes